This is the link to the news: https://www.neulandlabs.com/en/insights/stories/scaling-active-pharmaceutical-ingredient-api-chemistry-phase-3-clinical-trials-and
Neuland has been partnered with Karuna Therapeutics since KarXT’s Phase 3 trials. KarXT’s future will be decided by the USFDA today. BMS bought Karuna in Q3FY24 for $14 billion. According to BMS’ own expectations KarXT’s peak sales during the patent period could be upto $10 billion. These are some key points from my research over the years, please conduct your own as well before taking any investment decision.
Disc: invested from much lower levels.